军事知识服务平台
新生血管性青光眼是否难治
Current approaches in neovascular glaucoma
摘要 新生血管性青光眼(NVG)是临床眼科医师感到非常棘手的病征.以往对眼压难以控制、视功能差的患者,多采用睫状体冷凝或眼球摘除术等.随着近年来眼科诊疗技术的飞速发展,NVG这一顽疾的治疗方式也获得突破.如房水引流阀植入术治疗NVG已显示出良好的应用前景,可为治疗NVG的原发病带来一段眼压正常的“时间窗”;全视网膜光凝或抗血管内皮生长因子(VEGF)治疗可促使虹膜新生血管消退,为实施青光眼手术创造了条件.目前,以抗VEGF为核心的NVG治疗策略提高了NVG的手术成功率.积极治疗原发病是预防NVG的关键,尽全力保留或挽救患者视功能是治疗NVG的目标.NVG治疗应依据患者的发病病因、疾病进展分期、视功能存留等因素进行综合考虑,以制订科学而合理的个体化治疗方案.
Abstract:
Neovascular glaucoma (NVG) has long been recognized as a very difficult case to manage for its very poor prognosis of visual function,NVG is also remarked as an ' end stage' of ocular diseases.Conventional treatments with extremely uncontrolled cases are retinal cryotherapy or enucleation.Currently,management of this medical condition is directed toward a new era with great advancement in diagnosis and treatment. Glaucoma drainage implant surgery brings a time window of normal range of intraocular pressure (IOP) for physicians to process underlying disease of NVG. Regression of iris neovascularization by employing panretinal photocoagulation (PRP) or intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) antibodies create a chance to undertaken antiglaucomatous surgery.Adjunctive anti-VEGF treatment promotes the surgical success rate for NVG.Current approaches in NVG are able to provide patients with an individualized management using a sound treatment strategy according to etiology,stage of disease,visual potential and other factors.
作者: 张秀兰
Author: ZHANG Xiu-lan
作者单位: 中山大学中山眼科中心眼科学国家重点实验室,广州,510060
刊 名 中华眼科杂志 ISTICPKU
年,卷(期): 2012, 48(6)
分类号: R77
机标分类号: R77 R76
在线出版日期: 2012年8月31日